Artes Medical - Worst Pharma Stocks of 2007
Company:Â Artes Medical
Starting stock price: $8.33
Ending stock price: $2.27
Percent Change: -72.75%
Details: Artes Medical develops and markets injectable products for cosmetic use by dermatologists and plastic surgeons. Its first product, ArteFill, won FDA approval in October 2006 and started shipping in 2007. It competes with collagen injections and Botox.
More stories about Artes Medical
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: